Akebia Therapeutics Inc (AKBA)
1.79
-0.07
(-3.76%)
USD |
NASDAQ |
Nov 15, 16:00
1.795
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Research and Development Expense (TTM): 35.73M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
Date | Value |
---|---|
September 30, 2024 | 35.73M |
June 30, 2024 | 40.57M |
March 31, 2024 | 53.12M |
December 31, 2023 | 63.08M |
September 30, 2023 | 85.31M |
June 30, 2023 | 100.01M |
March 31, 2023 | 105.84M |
December 31, 2022 | 129.99M |
September 30, 2022 | 127.44M |
June 30, 2022 | 139.89M |
March 31, 2022 | 151.07M |
December 31, 2021 | 147.85M |
September 30, 2021 | 155.87M |
June 30, 2021 | 162.26M |
March 31, 2021 | 177.86M |
December 31, 2020 | 218.48M |
September 30, 2020 | 261.32M |
June 30, 2020 | 288.97M |
March 31, 2020 | 321.85M |
December 31, 2019 | 322.97M |
September 30, 2019 | 329.61M |
June 30, 2019 | 325.73M |
Date | Value |
---|---|
March 31, 2019 | 311.95M |
December 31, 2018 | 291.01M |
September 30, 2018 | 272.34M |
June 30, 2018 | 260.41M |
March 31, 2018 | 232.25M |
December 31, 2017 | 230.89M |
September 30, 2017 | 195.95M |
June 30, 2017 | 168.47M |
March 31, 2017 | 155.60M |
December 31, 2016 | 115.78M |
September 30, 2016 | 96.59M |
June 30, 2016 | 80.96M |
March 31, 2016 | 56.59M |
December 31, 2015 | 43.02M |
September 30, 2015 | 33.71M |
June 30, 2015 | 24.75M |
March 31, 2015 | 23.77M |
December 31, 2014 | 23.26M |
September 30, 2014 | 19.64M |
June 30, 2014 | 16.23M |
March 31, 2014 | 13.16M |
December 31, 2013 | 8.902M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
35.73M
Minimum
Sep 2024
322.97M
Maximum
Dec 2019
154.48M
Average
143.87M
Median
Research and Development Expense (TTM) Benchmarks
Corcept Therapeutics Inc | 231.29M |
Eli Lilly and Co | 10.53B |
Bioventus Inc | 13.66M |
NovaBay Pharmaceuticals Inc | 0.064M |
Palatin Technologies Inc | 22.40M |